Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Trump Says Anthropic No Longer Seen as National Security Threat 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
CHAPEL HILL, N.C., Feb. 03, 2016 -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the 5th Annual Leerink Partners Global Healthcare Conference. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, is scheduled to present at 8:25 a.m. ET on Wednesday, February 10, 2016 at the Waldorf Astoria in New York.
A live audio webcast and archive of the presentation will be available on the company website at http://investor.cempra.com/events.cfm. Listeners are encouraged to visit the site prior to the scheduled presentation to register, download and install any necessary audio software.
About Cempra, Inc.
Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) has successfully completed two Phase 3 clinical trials for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use. Three formulations, intravenous, oral capsules and a suspension formulation are in a Phase 1b trial in children from birth to 17 years of age. Taksta™ is Cempra's second product candidate, which is being developed for acute bacterial skin and skin structure Infections (ABSSSI) and is also expected to be tested in an exploratory study for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com.
Contacts: Investor Contact: Robert H. Uhl Westwicke Partners, LLC (858) 356-5932 [email protected] Media Contact: Tony Plohoros 6 Degrees (908) 591-2839 [email protected]
